Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06181006 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Pirtobrutinib (LOXO-305) in Healthy Adult Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT06181006 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 24 participants.
The verdict
NCT06181006, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the safety and tolerability of pirtobrutinib and to look at the amount of the study drug, pirtobrutinib, that gets into the blood stream and how long it takes the body to get rid of it when given in healthy adult participants. For each participant, the total duration of the study will be 46 days, including screening.
Interventions
- DRUG Pirtobrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-08-14 |
| Est. Completion | 2020-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06181006
The ClinicalTrials.gov registry entry for NCT06181006 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pirtobrutinib is the first listed.
NCT06181006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06181006 about?
NCT06181006 is a clinical study titled "A Study to Evaluate Pirtobrutinib (LOXO-305) in Healthy Adult Participants". The main purpose of this study is to assess the safety and tolerability of pirtobrutinib and to look at the amount of the study drug, pirtobrutinib, that gets into the blood stream and how long it takes the body to get rid of it when given in healthy adult participants. For each participant, the tot...
What is the current status of trial NCT06181006?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2020-08-14. Estimated completion is 2020-12-01.
What interventions are being tested in trial NCT06181006?
The interventions under investigation include: Pirtobrutinib (DRUG).
Who is sponsoring clinical trial NCT06181006?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.